#### SECOND REGULAR SESSION

# **HOUSE BILL NO. 2653**

### 101ST GENERAL ASSEMBLY

#### INTRODUCED BY REPRESENTATIVE BLAND MANLOVE.

5487H.01I

3

5 6

7

DANA RADEMAN MILLER, Chief Clerk

## AN ACT

To amend chapters 9 and 208, RSMo, by adding thereto two new sections relating to sickle cell disease.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Chapters 9 and 208, RSMo, are amended by adding thereto two new 2 sections, to be known as sections 9.236 and 208.184, to read as follows:

- 9.236. The third full week in September of each year shall be known and designated as "Sickle Cell Awareness Week". Sickle cell disease is a genetic disease in which a person's body produces abnormally shaped red blood cells that resemble a crescent and that do not last as long as normal round red blood cells, which leads to anemia. It is recommended to the people of the state that the week be appropriately observed through activities that will increase awareness of sickle cell disease and efforts to improve treatment options for patients.
- 208.184. 1. The MO HealthNet division shall conduct an annual review of medications and forms of treatment for sickle cell disease and services for MO HealthNet beneficiaries with a diagnosis of sickle cell disease. The review shall:
  - (1) Evaluate whether the available covered medications, treatments, and services are adequate to meet the needs of MO HealthNet beneficiaries with a diagnosis of sickle cell disease;
  - (2) Include information on treatments for sickle cell disease in late-stage studies that show promise in peer-reviewed medical literature; and
- 9 (3) Highlight provider and patient education on the disproportionate impact of 10 sickle cell disease on specific minority populations.

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

HB 2653 2

14

2. In conducting the annual review, the MO HealthNet division shall solicit and 11 12 consider input from persons or groups with knowledge and experience in sickle cell 13 disease treatment.

3. The MO HealthNet division shall make the annual review available to the 15 public on its website and provide a copy of the review to the speaker of the house of 16 representatives and the president pro tempore of the senate.